1. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
- Author
-
Hansol Lee, Camelia Quek, Ines Silva, Annie Tasker, Marcel Batten, Helen Rizos, Su Yin Lim, Tuba Nur Gide, Ping Shang, Grace H. Attrill, Jason Madore, Jarem Edwards, Matteo S. Carlino, Alexander Guminski, Robyn P.M. Saw, John F. Thompson, Peter M. Ferguson, Umaimainthan Palendira, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, and James S. Wilmott
- Subjects
melanoma ,nk cells ,mhc class i ,anti-pd-1 therapy ,Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: Anti-PD-1 therapy has revolutionized the treatment and improved the survival of stage IV melanoma patients. However, almost half of the patients fail to respond due to immune evasive mechanism. A known mechanism is the downregulation of major histocompatibility complex (MHC) class I expression, which prevents T cell recognition of the tumor. This study determined the relationship between natural killer (NK) cell numbers and clinical response to anti-PD-1 therapy in metastatic melanoma. Experimental Design: Twenty-five anti-PD-1 treated metastatic melanoma patients were categorized into responders (complete response (CR)/partial response (PR)/stable disease (SD) ≥ 6 mo, n = 13) and non-responders (SD
- Published
- 2019
- Full Text
- View/download PDF